Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan
Authors:
- on behalf of the SToP-BPD study groupOGon behalf of the SToP-BPD study group
- Wes OnlandWOWes Onland
- Maruschka P. MerkusMMMaruschka P. Merkus
- Debbie H. NuytemansDNDebbie H. Nuytemans
- Marijke C. Jansen-Van der WeideMWMarijke C. Jansen-Van der Weide
- Rebecca HolmanRHRebecca Holman
- Anton H. van KaamAKAnton H. van Kaam
Open Access
- 9 March 2018
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 19 (1) , 1-10
Abstract
Bronchopulmonary dysplasia (BPD) is the most common complication of preterm birth with short-term and long-term adverse consequences. Although the glucocorticoid dexamethasone has been proven to be beneficial for the prevention of BPD, there are concerns about an increased risk of adverse neurodevelopmental outcome. Hydrocortisone has been suggested as an alternative therapy. The aim of the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (SToP-BPD) trial is to assess the efficacy and safety of postnatal hydrocortisone administration for the reduction of death or BPD in ventilator-dependent preterm infants. The SToP-BPD study is a multicentre, double-blind, placebo-controlled hydrocortisone trial in preterm infants at risk for BPD. After parental informed consent is obtained, ventilator-dependent infants are randomly allocated to hydrocortisone or placebo treatment during a 22-day period. The primary outcome measure is the composite outcome of death or BPD at 36 weeks postmenstrual age. Secondary outcomes are short-term effects on pulmonary condition and long-term neurodevelopmental sequelae assessed at 2 years corrected age. Complications of treatment, other serious adverse events and suspected unexpected serious adverse reactions are reported as safety outcomes. This pre-specified statistical analysis plan was written and submitted without knowledge of the unblinded data. Netherlands Trial Register, NTR2768 . Registered on 17 February 2011. EudraCT, 2010-023777-19. Registered on 2 November 2010.Keywords
Funding Information
- ZonMw (11-32010-02)
This publication has 33 references indexed in Scilit:
- Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trialBMC Pediatrics, 2011
- Necrotizing EnterocolitisNew England Journal of Medicine, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary DysplasiaPediatrics, 2010
- Open-Label Glucocorticoids Modulate Dexamethasone Trial Results in Preterm InfantsPediatrics, 2010
- Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled TrialsPediatrics, 2009
- Effects of Higher Versus Lower Dexamethasone Doses on Pulmonary and Neurodevelopmental Sequelae in Preterm Infants at Risk for Chronic Lung Disease: A Meta-analysisPediatrics, 2008
- Trends in neonatal morbidity and mortality for very low birthweight infantsAmerican Journal of Obstetrics and Gynecology, 2007
- Extremely Low Birthweight Neonates with Protracted Ventilation: Mortality and 18-Month Neurodevelopmental OutcomesThe Journal of Pediatrics, 2005
- Impact of a Physiologic Definition on Bronchopulmonary Dysplasia RatesPediatrics, 2004